In this study we compared PT-IgG avidity in pregnant women and their infants following vaccination during pregnancy (20–33 weeks gestation) with one of four different formulations of a recombinant acellular pertussis vaccine containing variable amounts of PTgen compared with chemically inactivated acellular pertussis booster vaccine. The gene discussed is F2; the disease is pertussis.